FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:60-61 January 7, 1999 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The PURSUIT Trial Investigators

To the Editor: In the report on patients undergoing early coronary revascularization (within 72 hours) in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial (Aug. 13 issue),¹ the investigators state that there was a 31 percent reduction in the incidence of the 30-day combined end point of death or nonfatal myocardial infarction in patients receiving eptifibatide as compared with those receiving placebo (11.6 percent vs. 16.7 percent, P=0.01). However, it is not immediately clear from the data presented in Table 3 that there was, in fact, a significant difference in the outcome at 30 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.